Drug intelligence / Profile preview

WTX-116

Development stage: Discontinued
Lead developer: Westlake Therapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

WTX-116 is an erythro-drug conjugate (a type of antibody-drug conjugate) developed by Westlake Therapeutics for the treatment of metabolic diseases, with a particular focus on cardiovascular diseases and thrombosis. The drug was in early-stage research in China but has since been discontinued. As an erythro-drug conjugate, it likely utilizes red blood cell targeting or modification to deliver its therapeutic payload, although specific details about its mechanism of action or molecular targets have not been disclosed publicly[1][2].

Beyond the preview

Go deeper on WTX-116.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WTX-116.

Explore the full profile